232 related articles for article (PubMed ID: 21514531)
1. [Physiopathology and new therapeutic strategies in the management of bone metastases of prostate cancer].
Lebret T; Méjean A; Houédé N
Prog Urol; 2011 May; 21(5):301-7. PubMed ID: 21514531
[TBL] [Abstract][Full Text] [Related]
2. [The role of RANK/RANKL/osteoprotegerin (OPG) triad in cancer-induced bone diseases: physiopathology and clinical implications].
Clézardin P
Bull Cancer; 2011 Jul; 98(7):837-46. PubMed ID: 21700551
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonates for treatment and prevention of bone metastases.
Michaelson MD; Smith MR
J Clin Oncol; 2005 Nov; 23(32):8219-24. PubMed ID: 16278476
[TBL] [Abstract][Full Text] [Related]
4. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
Mori K; Le Goff B; Charrier C; Battaglia S; Heymann D; Rédini F
Bone; 2007 Apr; 40(4):981-90. PubMed ID: 17196895
[TBL] [Abstract][Full Text] [Related]
5. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician.
Higano CS
Urol Clin North Am; 2004 May; 31(2):331-52. PubMed ID: 15123412
[TBL] [Abstract][Full Text] [Related]
6. Prostate cancer, serum parathyroid hormone, and the progression of skeletal metastases.
Schwartz GG
Cancer Epidemiol Biomarkers Prev; 2008 Mar; 17(3):478-83. PubMed ID: 18349265
[TBL] [Abstract][Full Text] [Related]
7. Natural history and treatment of bone complications in prostate cancer.
Saad F; Clarke N; Colombel M
Eur Urol; 2006 Mar; 49(3):429-40. PubMed ID: 16431012
[TBL] [Abstract][Full Text] [Related]
8. [Anti-RANKL antibody for the management of bone metastasis].
Yoneda T
Gan To Kagaku Ryoho; 2011 Sep; 38(9):1439-45. PubMed ID: 21918338
[TBL] [Abstract][Full Text] [Related]
9. Targeting the receptor activator of nuclear factor-kappaB (RANK) ligand in prostate cancer bone metastases.
Saad F; Markus R; Goessl C
BJU Int; 2008 May; 101(9):1071-5. PubMed ID: 18070191
[TBL] [Abstract][Full Text] [Related]
10. Painful osseous metastases.
Smith HS
Pain Physician; 2011; 14(4):E373-403. PubMed ID: 21785487
[TBL] [Abstract][Full Text] [Related]
11. Bone health in men with prostate cancer: diagnostic and therapeutic considerations.
Saad F; Perrotte P; Bénard F; McCormack M; Karakiewicz PI
Can J Urol; 2005 Jun; 12 Suppl 2():9-15. PubMed ID: 16018826
[TBL] [Abstract][Full Text] [Related]
12. Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis.
Saad F; McKiernan J; Eastham J
Urol Oncol; 2006; 24(1):4-12. PubMed ID: 16414486
[TBL] [Abstract][Full Text] [Related]
13. The role of bisphosphonates in the management of bone metastases in prostate cancer.
Saad F; Chi K; Fleshner N
Can J Urol; 2004 Oct; 11(5):2376-82. PubMed ID: 15576002
[TBL] [Abstract][Full Text] [Related]
14. Bisphosphonates for cancer patients: why, how, and when?
Body JJ; Mancini I
Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
[TBL] [Abstract][Full Text] [Related]
15. Advances in the treatment of bone metastases.
Reich CD
Clin J Oncol Nurs; 2003; 7(6):641-6. PubMed ID: 14705479
[TBL] [Abstract][Full Text] [Related]
16. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.
Armstrong AP; Miller RE; Jones JC; Zhang J; Keller ET; Dougall WC
Prostate; 2008 Jan; 68(1):92-104. PubMed ID: 18008334
[TBL] [Abstract][Full Text] [Related]
17. Prostate cancer and bone metastases: medical treatment.
Clark PE; Torti FM
Clin Orthop Relat Res; 2003 Oct; (415 Suppl):S148-57. PubMed ID: 14600605
[TBL] [Abstract][Full Text] [Related]
18. [Physiopathology, diagnosis and management of bone metastases from prostate cancer].
Lebret T; Méjean A
Prog Urol; 2008 Nov; 18 Suppl 7():S349-56. PubMed ID: 19070815
[TBL] [Abstract][Full Text] [Related]
19. Bone metastases in prostate cancer: a targeted approach.
Storey JA; Torti FM
Curr Opin Oncol; 2007 May; 19(3):254-8. PubMed ID: 17414645
[TBL] [Abstract][Full Text] [Related]
20. Skeletal morbidity in men with prostate cancer: quality-of-life considerations throughout the continuum of care.
Saad F; Olsson C; Schulman CC
Eur Urol; 2004 Dec; 46(6):731-39; discussion 739-40. PubMed ID: 15548440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
